Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1812 results about "Adenosine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Adenosine is both a chemical found in many living systems and a medication. As a medication it is used to treat certain forms of supraventricular tachycardia that do not improve with vagal maneuvers. Common side effects include chest pain, feeling faint, shortness of breath and tingling of the senses. Serious side effects include increased dysrhythmia and reduced blood pressure. It appears to be safe in pregnancy.
Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone
A method and composition for reducing adenosine levels comprises administering a dehydroepiandrosterone, and optionally a ubiquinone.
Owner:EAST CAROLINA UNIVERISTY
Homotypic cysteine measuring method and its reagent
ActiveCN1560610AAbsorbance value dropsHigh sensitivityMaterial analysis by observing effect on chemical indicatorBiological testingAdenosineHomocysteine measurement
The invention relates to an enzymology measuring method and reagent with circular increment technology, applied to measure the content of homeotypic cysteine in the measured sample. The character is: with a circular increment technology, increases the measurement sensitivity, thus it can carries on automatic measurement to the homeotypic cysteine in the sample liquid like normal enzymology diagnosing agent. The homeotypic cysteine in the sample liquid reacts with the S-adenosine-L-methionine repeatedly and circularly under the effect of homeotypic cysteine methyl kinase and adenosine homeotypic cysteine, generates the adenosine, the speed of the adenosine generation is in direct proportion to the homeotypic cysteine in the sample, through the generation speed, the aim to measure the content of the homeotypic cysteine in sample can be achieved.
Owner:北京安百胜诊断科技有限公司 +1
Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP)
The present invention relates to a series of substituted indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and / or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
Owner:AVENTIS PHARMA INC
Targeted pre-mRNA/mRNA modification and gene regulation
ActiveUS20070141030A1Easy to identifyLarge productionBiocideGenetic material ingredientsAdenosinePrecursor mRNA
Methods for affecting mRNA expression or translation through the modification of pre-mRNA or mRNA transcripts are described. In one embodiment of the methods of the present invention, the branch point adenosine of a pre-mRNA transcript is 2′-O-methylated to block splicing and subsequent expression of the protein encoded by the transcript. In another embodiment, a uridine residue in a nonsense stop codon may be modified to pseudouridine, causing the translation machinery to read through the nonsense stop codon and translate a full length protein.
Owner:UNIVERSITY OF ROCHESTER
Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
InactiveUS20080051379A1High level of apoptosisLevel of apoptosis inducedOrganic active ingredientsBiocidePDE4 InhibitorsAdenosine
The present invention is directed to the use of a PDE4 inhibitor and a glucocorticoid to treat peripheral B-cell neoplasms. In particular, the present invention provides a method of treating individuals (e.g. patients) diagnosed with peripheral B-cell leukemias by administering pharmaceutical compositions comprising Type 4 cyclic adenosine monophosphate phosphodiesterase inhibitors and a glucocorticoid. Preferably, the combination of the PDE4 inhibitor and the glucocorticoid has a synergistic effect on apoptosis such that the level of apoptosis induced is greater than the level that would be expected by simply adding a PDE4 inhibitor to a glucocorticoid.
Owner:BOSTON MEDICAL CENTER INC
Personal care compositions and methods for the beautification of mammalian skin and hair
Personal care composition comprising from about 0.05% to about 5% of at least one aquaporin-stimulating compound selected from the group consisting of xanthine, caffeine; 2-amino-6-methyl-mercaptopurine; 1-methyl xanthine; 2-aminopurine; theophylline; theobromine; adenine; adenosine; kinetin; p-chlorophenoxyacetic acid; 2,4-dichlorophenoxyacetic acid; indole-3-butyric acid; indole-3-acetic acid methyl ester; beta-naphthoxyacetic acid; 2,3,5-triiodobenzoic acid; adenine hemisulfate; n-benzyl-9-(2-tetrahydropyranyl)adenine; 1,3-diphenylurea; 1-phenyl-3-(1,2,3-thiadiazol-5-yl)urea; zeatin; indole-3-acetic acid; 6-benzylaminopurine; alpha-napthaleneacetic acid; 6-2-furoylaminopurine; green tea extract; white tea extract; menthol; tea tree oil; ginsenoside-RB1; ginsenoside-RB3; ginsenoside-RC; ginsenoside-RD; ginsenoside-RE; ginsenoside-RG1; ginseng root extract; ginseng flower extract; pomegranate extract, extracts from Ajuga turkestanica; extracts from viola tricolor and combinations thereof; an additional ingredient selected from the group consisting of niacinamide, glycerin and mixtures thereof, and a dermatologically-acceptable carrier.
Owner:THE PROCTER & GAMBLE COMPANY
Nitrosated and/or nitrosylated compounds, compositions and methods of use
The invention describes novel nitrosated and / or nitrosylated compounds of the invention and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, and at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel kits comprising at least one compound of the invention, that is optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The nitrosated and / or nitrosylated compounds of the invention are preferably nitrosated and / or nitrosylated antimicrobial compounds, nitrosated and / or nitrosylated adenosine antagonists, nitrosated and / or nitrosylated LTB4 antagonists, nitrosated and / or nitrosylated mucoregulators and nitrosated and / or nitrosylated purine agonists. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis.
Owner:NICOX SA
Method of identifying therapies for pulmonary hypertension
ActiveUS20130184295A1High activityBiocideOrganic active ingredientsPhosphodiesterase 5 inhibitorPde5 inhibition
The present invention is directed to a method of screening for a therapeutic agent useful for treating pulmonary hypertension comprising: contacting an erythrocyte with a candidate therapeutic agent; and detecting a presence or absence of erythrocyte-derived adenosine triphosphate, wherein a greater erythrocyte-derived adenosine triphosphate level indicates the candidate therapeutic agent has greater activity in treating pulmonary hypertension. Additionally, the present invention is directed to methods of treating pulmonary arterial hypertension by stimulating ATP release from erythrocytes through co-administration to a subject in need thereof an amount of a PDE5 inhibitor compound, and an amount of a prostacyclin compound.
Owner:UNITED THERAPEUTICS CORP
Compositions containing a combination of a creatine compound and a second agent
The present invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds in combination with neuroprotective agents can be used as therapeutically effective compositions against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compounds which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compounds which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of adenosine triphosphate (ATP) and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing non-transferable moieties which mimic the N-phosphoryl group.
Owner:THE GENERAL HOSPITAL CORP
2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
InactiveUS7214665B2Inhibit the inflammatory responseInhibit inflammationBiocideSenses disorderAdenosineStereochemistry
Owner:VIRGINIA UNIV OF +1
Prophylatic and/or therapeutic agents for chronic musculoskeletal pain
A prophylactic and / or therapeutic agent for diseases accompanied by chronic musculoskeletal pain comprising as an active ingredient a compound having an adenosine A2A receptor antagonistic action, for example, represented by the following formula (I) (wherein R1, R2 and R3 are the same or different, each representing a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R4 represents cycloalkyl, —(CH2)n—R5 or the following formula (II); and X1 and X2 are the same or different, each representing an oxygen atom or a sulfur atom) or a pharmaceutically acceptable salt thereof.
Owner:KYOWA HAKKO KIRIN CO LTD
N-pyrazole A2A receptor agonists
Owner:TPG AXON LEX SUB TRUST +1
2-polycyclic propynyl adenosine analogs having A2A agonist activity
ActiveUS20060040889A1Profound benefitUseful in treatmentBiocideIn-vivo radioactive preparationsAdenosineAgonist
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND +1
Compositions and methods for the treatment of immunoinflammatory disorders
InactiveUS20070213296A1Increased effectiveness and safety and tolerability and satisfactionImprove effectivenessBiocideNervous disorderAdenosinePharmacology
The invention features methods and kits for treating an immunoinflammatory disorder, by administering to a patient diagnosed with or at risk of developing such immunoinflammatory disorder an adenosine activity upregulator in combination with one or more additional agents.
Owner:COMBINATORX
Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
InactiveUS20050165030A1Increase antiplatelet effectIncrease vasodilationBiocideMuscular disorderDipyridamoleAdenosine
The present invention relates to pharmaceutical compositions comprising at least one multifunctional phosphodiesterase inhibitor (MPDEI) and at least one adenosine uptake inhibitor. The present invention also relates to compositions comprising cilostazol and dipyridamole and their use.
Owner:OTSUKA PHARM CO LTD
Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof
InactiveUS20130040898A1Impair thrombus formationIncreased riskElcosanoid active ingredientsInorganic active ingredientsBeta blockerPlatelet inhibitors
The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and / or no-reflow phenomena and / or ischemia-reperfusion injury by administration of agent(s) modulating and / or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb / IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine, Beta-blockers and surgical methods such as percutaneous coronary intervention (PCI), PCI with thrombus aspiration, PCI with stents.
Owner:THROMBOLOGIC
Compositions of S-adenosyl-L-methionine
InactiveUS20060127506A1Good curative effectAccumulate in bloodBiocideCarbohydrate active ingredientsS-Adenosyl-l-methionineAdenosine
Owner:HEBERT SAM E
2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
Compounds are disclosed having the formulae: wherein R' is hydrogen, lower alkyl or lower alkoxy; r is 0 or 1 and p is zero to four; and wherein R1 is selected from the group, consisting of radicals represented by the general formulae: wherein Y is selected from the group consisting of lower alkyl, lower alkoxy, and halogen; Z is oxygen, sulfur or -NH, Q is -CH or nitrogen; a is zero or an integer of from one to three; and wherein, R2 is selected from the group consisting of hydrogen and straight chain, branched and cyclic hydrocarbyl radicals having from one to four carbon atoms, and optionally substituted with a hydroxyl radical; and wherein X is two hydrogen atoms or oxygen and B is selected from oxygen and nitrogen, and pharmaceutically acceptable salts thereof, with the proviso that when X is two hydrogen atoms, B is oxygen, and with the further proviso that when B is oxygen then R1 cannot be a phenyl or a substituted phenyl radical. Pharmaceutical preparations using these compounds and a method for inducing an adenosine response mediated by the adenosine A2 receptor by administering these compounds are also disclosed.
Owner:ADERIS PHARMA
Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.
Owner:INOTECK PHARMA CORP
Phenanthridinones as parp inhibitors
InactiveUS20050171101A1Enhance DNA repairExtended life spanAntibacterial agentsBiocideHydrogenAdenosine
A compound of the formula (I): wherein ring A is a carbocyclic group, R1 is hydrogen or a halogen atom or a lower alkyl group, R2 is a di(lower)alkylamino group or N-containing heterocyclic group, among which the N-containing heterocyclic group may be substituted with one or more substituent(s), Y is an oxygen or sulfur atom, n is an integer from 0 to 2, and m is an integer from 0 to 4, or its prodrug, or their salt which has poly(adenosine 5′-diphospho-ribose)polymerase inhibiting activity.
Owner:FUJISAWA PHARMA CO LTD
Anti-inflammatory compositions for treating multiple sclerosis
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containg one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT
Method for breeding cordyceps militaris by utilizing silkworm larvae
The invention relates to a novel method for breeding cordyceps militaris by utilizing silkworm larvae. The method comprises the steps of taking live matured silkworm as the host, vaccinating cordyceps militaris strains through an injection method, and promoting silkworm to sleep, and the vaccination attainment rate is improved; after the method is adopted, the inactivation rate of the silkworm larvae reaches 90% to 100%, and the outgrowth rate of fruiting body reaches 85% to 100%; moreover, the water-solubility protein, polysaccharide, cordycepic acid, cordycepin and adenosine of the cordyceps militaris bred by the method are higher than those of cordyceps militaris bred by silkworm chrysalis in content. The novel method for breeding cordyceps militaris by utilizing silkworm larvae has the advantages of convenience in operation, low breeding cost, good experiment repeatability and wide application prospect, and is suitable for large-scale cultivation.
Owner:北京航天农业生物科技有限公司
Lactobacillus casei strain and probiotic composition for lowering blood uric acid and application thereof
The invention provides a lactobacillus casei strain and a probiotic composition for lowering blood uric acid and application thereof, and belongs to the technical field of food medicines. The lactobacillus casei strain ZM15 for lowering the blood uric acid has the collection number of CGMCC No.13980. The lactobacillus casei strain ZM15 has the rates of degrading adenylic acid, guanylic acid, adenosine and guanosine as high as 100%; a degraded product does not contain uric acid and allantoin; in addition, the degraded product has a low purine base proportion of only 0.10%, so that the product can be prevented from being further decomposed into the uric acid, and the human blood uric acid content can be effectively reduced. The probiotic composition provided by the invention is obtained by compounding four strains of ZM15, ZM18, ZM122 and ZM05; through mutual coordination of the four strains, the blood uric acid lowering effect of the probiotic composition is significantly better than that during independent application of ZM15, ZM18, ZM122 and ZM05 strains, so that the blood uric acid lowering effect can be further improved.
Owner:JIAXING INNOCUL PROBIOTICS CO LTD
Ferment for producing aweto in large scale and technique for processing power of fungus
This invention describes the large-scale fermentation and processing of Chinese caterpillar fungus. In this invention, hirsutella sinensis strains are used as the fermentation strain and cultivated in the inclined plate and shaking-bottle. 3-5% of potato, 0.5-2% of soybean powders, 0.01-0.02% of soifnum muicfun, 0.01-0.02% of Chinese yam, 0.5-2% of protein, 0.5-5% of glucose, a small amount of dipotassium hydrogen phosphorus and magnesium sulfate, and water culture medium are successively directed into all levels of fermenter for fermentation and processing. The yield of the fermented product is 20% higher than that in the present processes, the fermentation periodic time is 12 days shorter, the cost is 20% lower and the pollution rate is 2% lower. Through the DNA molecular sequence examination by the institute of microbes, Chinese Academy of Sciences, the constitution of the fermented product is the same with that of natural Chinese caterpillar fungus, and the content of cordycepin, adenosine, Chinese caterpillar fungus polyoses, sterol, biological base, amino acids and trace elements is much higher than that in natural Chinese caterpillar fungus. The pharmacological action of the fermented product is better than that of natural Chinese caterpillar fungus.
Owner:YUEWANGQINGZANG PHARMA QINGHAI
Pyrazine derivatives and pharmaceutical use thereof
InactiveUS20050222159A1Treatment and/or prevention of Parkinson's diseaseEliminate side effectsSenses disorderNervous disorderPyrazineAdenosine
A pyrazine derivative of the following formula (I): wherein R1 is hydrogen or optionally substituted lower alkyl; X is hydrogen, halogen, hydroxy, cyano, acyl, or amino, aryl, heterocyclic group or the like; Y is hydrogen, halogen, hydroxy, acyl, amino, or the like; Z is aryl or heteroaryl, each of which is optionally substituted; or a salt thereof. The pyrazine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and / or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like.
Owner:ASTELLAS PHARMA INC
5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine mucliosidases (MTAN) and / or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
![5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/382d2696-421c-41ef-b7d6-97472bac8513/US07553839-20090630-D00001.png "5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases")
![5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/382d2696-421c-41ef-b7d6-97472bac8513/US07553839-20090630-D00002.png "5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases")
![5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/382d2696-421c-41ef-b7d6-97472bac8513/US07553839-20090630-C00001.png "5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases")
Owner:VICTORIA LINK LTD
Method and composition used for obtaining neuron-like cells from non-neuronal cells via reprogramming
ActiveCN105039258ALow costEasy to operateNervous disorderDrug screeningPTK InhibitorsEnzyme Inhibitor Agent
Owner:PEKING UNIV +1
Agents for intravitreal administration to treat or prevent disorders of the eye
InactiveUS20050137124A1Reduce chancePotential damageBiocideSalicyclic acid active ingredientsDiseaseUrea derivatives
Methods and preparations for treating disorders of the eye and / or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
Owner:KATO PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com